Autolus Therapeutics plc (NASDAQ:AUTL) Q3 2021 Earnings Conference Call November 3, 2021 8:30 AM ET Company Participants Dr. Lucinda Crabtree - Vice President of Business Planning and Strategy Dr. Christian Itin - Chief Executive Officer Christopher Vann - Chief Operating Officer Andrew Oakley - Chief Financial Officer Conference Call Participants Mara Goldstein - Mizuho Nishant Gandhi - Needham & Company Nick Abbott - Wells Fargo Asthika Goonewardene - Truist Securities Matt Phipps - William Blair Eric Jo ...

Financial Data and Key Metrics Changes - Cash and cash equivalents at June 30, 2021, totaled $216.4 million, down from $239 million at the end of Q1 2021 [37] - Total net operating expenses for Q2 2021 were $37.7 million, compared to $39.5 million for the same period in 2020 [37][38] - Net loss attributable to ordinary shareholders was $33.2 million for Q2 2021, compared to a loss of $32.1 million for the same period last year [42] Business Line Data and Key Metrics Changes - Research and development expenses increased to $32.1 million in Q2 2021 from $31.3 million in Q2 2020 [38] - General and administrative expenses decreased to $7.2 million in Q2 2021 from $8.5 million in Q2 2020 [40] Market Data and Key Metrics Changes - The company received PRIME designation from the European Medicines Agency and ILAP designation from the UK Medicines and Healthcare Agency, enhancing regulatory engagement [15][16] Company Strategy and Development Direction - The company is focused on executing the pivotal FELIX study for adult patients with relapsed/refractory ALL, which is one of the few pivotal studies in this area [44] - The company plans to provide updates on various indications, including pediatric ALL and non-Hodgkin's lymphoma, by the end of the year [45] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the stability in clinical trial enrollment due to increased vaccination rates and recovery from COVID-19 [10][11] - The company reiterated guidance for pivotal data to be available in 2022, maintaining confidence in the timelines for key studies [17][52] Other Important Information - The company sold approximately 2 million ADSs under the Open Market Sales Agreement, netting $14.3 million in additional capital [18] - A new Chief Development Officer and Head of Clinical Development were appointed, indicating a strengthening of the management team [19] Q&A Session Summary Question: What pushed back AUTO4 and AUTO5 to the first half of next year? - Management indicated that the impact on centers due to COVID-19 has been resolved, and they expect to enroll at the predicted rate moving forward [50] Question: Can you narrow the guidance for the FELIX study? - Management confirmed that the guidance remains unchanged, with primary endpoint data expected in the middle of next year [52] Question: What are the economics of the Moderna collaboration? - The collaboration includes option exercise fees, development milestones, commercial milestones, and royalties, but specific amounts were not disclosed [58] Question: How does the company view the competitive positioning of AUTO3 or AUTO1 in DLBCL? - Management noted that moving CAR-T therapy to earlier lines of treatment shows attractive outcomes compared to stem cell transplants, which will inform their strategy [59] Question: What feedback has been received regarding the Tecartus regulatory decision? - Management highlighted that while Tecartus shows some progress, the safety profile of their product indicates a significant improvement for patients [66] Question: Will the fully closed manufacturing process impact efficacy and cost of goods sold? - Management stated that the majority of patients are now manufactured using the enclosed system, which is expected to enhance efficacy, though the causal relationship is still being evaluated [84]

Exhibit 1 Registered Number 11185179 (England & Wales) Annual Report and Accounts for the year ended 31 December 2020 for Autolus Therapeutics pie AUTOLUS THERAPEUTICS PLC Company Information 3 Strategic Report 4 Directors' Report 11 Directors' Remuneration Report 18 Independent Auditor's Report to the Members of Autolus Therapeutics plc 43 Consolidated Income Statement for the 12 months ended 31 December 2020 51 Consolidated Balance Sheet 52 Consolidated Cash Flow Statement 53 Consolidated Statement of Cha ...

Autolus Therapeutics Plc (NASDAQ:AUTL) Q1 2021 Earnings Conference Call May 6, 2021 8:30 AM ET Company Participants Lucinda Crabtree - Vice President of Investor Relations Christian Itin - Chairman and Chief Executive Officer Andrew Oakley - Chief Financial Officer Conference Call Participants Mara Goldstein - Mizuho Matt Phipps - William Blair Gil Blum - Needham & Company Kelly Shi - Jefferies Asthika Goonewardene - Truist Operator Hello, ladies and gentlemen, and welcome to the Autolus Therapeutics First ...

Autolus Therapeutics plc (NASDAQ:AUTL) Q4 2020 Earnings Conference Call March 4, 2021 8:30 AM ET Company Participants Lucinda Crabtree – Vice President-Investor Relations Christian Itin – Chairman and Chief Executive Officer Andrew Oakley – Chief Financial Officer Conference Call Participants Hannah Adeoye – JP Morgan Mara Goldstein – Mizuho Ingrid Gafanhão – Kempen Matt Phipps – William Blair Nick Abbott – Wells Fargo Biren Amin – Jefferies Operator Hello, ladies and gentlemen, and welcome to the Autolus T ...

Autolus Therapeutics PLC (NASDAQ:AUTL) Q3 2020 Earnings Conference Call November 5, 2020 8:30 AM ET Company Participants Lucinda Crabtree - VP, IR & Corporate Communications Christian Itin - Chairman & CEO Andrew Oakley - CFO & SVP Conference Call Participants James Birchenough - Wells Fargo Securities Gil Blum - Needham & Company Gabriel Fung - Mizuho Securities Graig Suvannavejh - Goldman Sachs Group Dingding Shi - Jefferies Operator Hello, ladies and gentlemen, and welcome to the Autolus Therapeutics Thi ...